Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study
ConclusionGefitinib demonstrated modest anti-tumor activity and a manageable safety profile in chemotherapy-refractory solid tumors with EGFR amplification or sensitivity to an EGFR inhibitor identified through a drug-screening platform with PDCs.ClinicalTrials.gov identifierNCT02447419.
Source: Targeted Oncology - Category: Cancer & Oncology Source Type: research
More News: Cancer | Cancer & Oncology | Chemistry | Chemotherapy | Gastric (Stomach) Cancer | Gastroenterology | Rectal Cancers | Sarcomas | Skin | Study | Toxicology